{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:05Z","timestamp":1787019605673,"version":"build-2736575974"},"reference-count":116,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Thrombotic thrombocytopenic purpura (TTP) was first described just over a century ago, and it is now 25 years since the identification of ADAMTS13 as the enzyme deficient in both antibody-mediated immune TTP (iTTP) and congenital TTP (cTTP). The discovery of ADAMTS13 has been fundamental to the vast improvement seen in TTP outcomes. Understanding the interaction between ADAMTS13, platelets, and von Willebrand factor led to the development of clinical ADAMTS13 assays, and therefore quicker and accurate diagnosis, but also, critically, to novel therapies and monitoring of treatment. Landmark additions to iTTP therapy have included anti-CD20 treatment with rituximab, in both the acute and elective settings, and the use of the nanobody caplacizumab in acute TTP. In cTTP, the use of ADAMTS13 replacement is playing a role in reducing end-organ damage and morbidity, with recombinant ADAMTS13 (rADAMTS13) now representing the gold standard for cTTP. The ability to measure response to treatment by monitoring ADAMTS13 activity has underpinned these treatment advances, and allowed clinicians to tailor immunosuppressive treatment for iTTP and rADAMTS13 dosing in cTTP. Looking forward, there are many avenues for future development, with potential expansion of rADAMTS13 to treat iTTP, new, quicker assays to improve diagnosis, monitoring, and immunomodulatory therapeutic advancement, all underpinned by ADAMTS13. Future endeavors for the role of ADAMTS13 in other thrombotic indications open further exciting opportunities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030791","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:37:57Z","timestamp":1772476677000},"page":"2582-2591","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Thrombotic thrombocytopenic purpura: celebrating 25 years of ADAMTS13"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-6517","authenticated-orcid":false,"given":"Marie","family":"Scully","sequence":"first","affiliation":[{"name":"1Department of Haematology, University College London Hospitals and Haematology Programme, National Institute for Health Research, University College London Hospitals, University College London Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Carter","sequence":"additional","affiliation":[{"name":"2Haemostasis Research Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Subhan","sequence":"additional","affiliation":[{"name":"3Department of Haematology, University College London Hospital National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026052811215547700_bib1","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"issue":"1","key":"2026052811215547700_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","article-title":"A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency","volume":"16","author":"Schulman","year":"1960","journal-title":"Blood"},{"issue":"3","key":"2026052811215547700_bib3","first-page":"219","article-title":"Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura","volume":"13","author":"Bukowski","year":"1976","journal-title":"Semin Hematol"},{"issue":"3","key":"2026052811215547700_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood"},{"issue":"6","key":"2026052811215547700_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"2026052811215547700_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"2026052811215547700_bib7","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"issue":"9","key":"2026052811215547700_bib8","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"issue":"22","key":"2026052811215547700_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"2026052811215547700_bib10","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"6855","key":"2026052811215547700_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"44","key":"2026052811215547700_bib12","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem"},{"issue":"6","key":"2026052811215547700_bib13","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor-cleaving protease","volume":"98","author":"Gerritsen","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2026052811215547700_bib14","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2026052811215547700_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.jbchem.a003009","article-title":"A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?","volume":"130","author":"Soejima","year":"2001","journal-title":"J Biochem"},{"issue":"6","key":"2026052811215547700_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.V2.6.542.542","article-title":"Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses","volume":"2","author":"Singer","year":"1947","journal-title":"Blood"},{"issue":"11","key":"2026052811215547700_bib17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.2023022277","article-title":"Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome","volume":"144","author":"Cataland","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026052811215547700_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13059-015-0676-3","article-title":"The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family","volume":"16","author":"Kelwick","year":"2015","journal-title":"Genome Biol"},{"issue":"1","key":"2026052811215547700_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbrc.2003.11.111","article-title":"Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets","volume":"313","author":"Suzuki","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2026052811215547700_bib20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1538-7836.2006.01959.x","article-title":"Human endothelial cells synthesize and release ADAMTS-13","volume":"4","author":"Turner","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026052811215547700_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"Furlan","year":"1999","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026052811215547700_bib22","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41467-019-11474-5","article-title":"Crystal structure and substrate-induced activation of ADAMTS13","volume":"10","author":"Petri","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"2026052811215547700_bib23","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.V83.8.2171.2171","article-title":"Shear stress enhances the proteolysis of von Willebrand factor in normal plasma","volume":"83","author":"Tsai","year":"1994","journal-title":"Blood"},{"issue":"23","key":"2026052811215547700_bib24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"14","key":"2026052811215547700_bib25","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an International Working Group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026052811215547700_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2026052811215547700_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026052811215547700_bib28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"2026052811215547700_bib29","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"2026052811215547700_bib30","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026052811215547700_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052811215547700_bib32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.thromres.2014.09.006","article-title":"Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement","volume":"134","author":"Joly","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"2026052811215547700_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ijlh.13414","article-title":"Multicentric evaluation of the new HemosIL Acustar(\u00ae) chemiluminescence ADAMTS13 activity assay","volume":"43","author":"Pascual","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2026052811215547700_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.2025028416","article-title":"Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"146","author":"Deshpande","year":"2025","journal-title":"Blood"},{"issue":"7","key":"2026052811215547700_bib35","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jtha.2025.02.038","article-title":"Real-world evaluation of a novel automated method for measuring ADAMTS-13 activity using the Ceveron s100 analyzer","volume":"23","author":"Joly","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026052811215547700_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","article-title":"Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies","volume":"5","author":"Meyer","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026052811215547700_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026052811215547700_bib38","doi-asserted-by":"crossref","first-page":"100108","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026052811215547700_bib39","unstructured":"Federal Institute for Drugs and Medical Devices. Urgent Field Safety Notice for HemosIL AcuStar ADAMTS13-Activity Assay by Instrumentation Laboratory Co. Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). 2022. Accessed 23 March 2026. https:\/\/www.bfarm.de\/SharedDocs\/Kundeninfos\/EN\/08\/2022\/04426-22_kundeninfo_en.pdf."},{"issue":"10","key":"2026052811215547700_bib40","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Ferrari","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026052811215547700_bib41","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2026052811215547700_bib42","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2026052811215547700_bib43","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2009-06-229203","article-title":"An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF","volume":"115","author":"Pos","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026052811215547700_bib44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3324\/haematol.2010.036327","article-title":"Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain","volume":"96","author":"Pos","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2026052811215547700_bib45","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3324\/haematol.2019.226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Gra\u00e7a","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2026052811215547700_bib46","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1538-7836.2006.02164.x","article-title":"Multiple B-cell clones producing antibodies directed to the spacer and disintegrin\/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Luken","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026052811215547700_bib47","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.019299","article-title":"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura","volume":"95","author":"Zheng","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2026052811215547700_bib48","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"2026052811215547700_bib49","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1055\/s-0038-1672187","article-title":"Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura","volume":"2","author":"Vendramin","year":"2018","journal-title":"TH Open"},{"issue":"9","key":"2026052811215547700_bib50","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2026052811215547700_bib51","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026052811215547700_bib52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2006.01833.x","article-title":"ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences","volume":"4","author":"Feys","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026052811215547700_bib53","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1055\/s-0038-1669459","article-title":"Anti-ADAMTS13 autoantibodies against cryptic epitopes in immune-mediated thrombotic thrombocytopenic purpura","volume":"118","author":"Roose","year":"2018","journal-title":"Thromb Haemost"},{"issue":"2","key":"2026052811215547700_bib54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"25","key":"2026052811215547700_bib55","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.2023023269","article-title":"Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura","volume":"143","author":"Prasannan","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026052811215547700_bib56","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/jcm13051342","article-title":"Real-world data analysis of patients affected by immune-mediated thrombotic thrombocytopenic purpura in Italy","volume":"13","author":"Angelucci","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"2026052811215547700_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18651","article-title":"A 'needle in a haystack': drug-induced thrombotic thrombocytopenic purpura-association or causality?","volume":"201","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"2026052811215547700_bib58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1538-7836.2008.02846.x","article-title":"Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura","volume":"6","author":"Camilleri","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026052811215547700_bib59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence","volume":"14","author":"von Krogh","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"16","key":"2026052811215547700_bib60","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/bloodadvances.2024013421","article-title":"Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis","volume":"8","author":"Seidizadeh","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2026052811215547700_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jca.1025","article-title":"Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura","volume":"16","author":"Reutter","year":"2001","journal-title":"J Clin Apher"},{"issue":"6","key":"2026052811215547700_bib62","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/trf.17836","article-title":"Thirty years of experience with solvent\/detergent-treated plasma for transfusion medicine","volume":"64","author":"Racine-Brzostek","year":"2024","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"2026052811215547700_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"2026052811215547700_bib64","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"Mintz","year":"2006","journal-title":"Transfusion (Paris)"},{"issue":"6","key":"2026052811215547700_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"23","key":"2026052811215547700_bib66","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2026052811215547700_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"issue":"6","key":"2026052811215547700_bib68","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026052811215547700_bib69","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"7","key":"2026052811215547700_bib70","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2026052811215547700_bib71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026052811215547700_bib72","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026052811215547700_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"key":"2026052811215547700_bib74","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"20","key":"2026052811215547700_bib75","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2026052811215547700_bib76","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"2026052811215547700_bib77","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion (Paris)"},{"issue":"9","key":"2026052811215547700_bib78","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780390906","article-title":"Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus","volume":"39","author":"Pryor","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2026052811215547700_bib79","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"2026052811215547700_bib80","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1016\/j.jtha.2025.07.012","article-title":"Splenectomy for immune thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"23","author":"Deshpande","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"18","key":"2026052811215547700_bib81","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/bloodadvances.2022007632","article-title":"Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura","volume":"6","author":"Bichard","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2026052811215547700_bib82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13886","article-title":"Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura","volume":"110","author":"Comparon","year":"2023","journal-title":"Eur J Haematol"},{"key":"2026052811215547700_bib83","article-title":"Efficacy and safety of obinutuzumab in immune-mediated thrombotic thrombocytopenic purpura","author":"Weisinger","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"2026052811215547700_bib84","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052811215547700_bib85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2026052811215547700_bib86","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.18854","article-title":"Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura","volume":"202","author":"Aggarwal","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052811215547700_bib87","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/bjh.19752","article-title":"Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura","volume":"205","author":"Weisinger","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"2026052811215547700_bib88","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026052811215547700_bib89","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2026052811215547700_bib90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"2026052811215547700_bib91","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2026052811215547700_bib92","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026052811215547700_bib93","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1016\/j.bvth.2024.100008","article-title":"Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab","volume":"1","author":"Dierickx","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"24","key":"2026052811215547700_bib94","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"key":"2026052811215547700_bib95","doi-asserted-by":"crossref","first-page":"1226114","DOI":"10.3389\/fmed.2023.1226114","article-title":"Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data","volume":"10","author":"Gavriilaki","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2026052811215547700_bib96","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s12185-015-1887-9","article-title":"Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy","volume":"102","author":"Miyakawa","year":"2015","journal-title":"Int J Hematol"},{"key":"2026052811215547700_bib97","doi-asserted-by":"crossref","first-page":"103168","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (The Capla 1000+ project)","volume":"82","author":"Coppo","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2026052811215547700_bib98","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"K\u00fchne","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026052811215547700_bib99","article-title":"Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura","volume":"9","author":"Coppo","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026052811215547700_bib100","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"Borogovac","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026052811215547700_bib101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","journal-title":"Br J Haematol"},{"issue":"7","key":"2026052811215547700_bib102","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MPH.0000000000000917","article-title":"Treatment of congenital thrombotic thrombocytopenia purpura: a new paradigm","volume":"39","author":"Aledort","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"25","key":"2026052811215547700_bib103","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in severe neonatal thrombotic thrombocytopenic purpura","volume":"387","author":"Stubbs","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026052811215547700_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2006-939764","article-title":"Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children","volume":"32","author":"Loirat","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"15","key":"2026052811215547700_bib105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026052811215547700_bib106","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrolment until 2017","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"2026052811215547700_bib107","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.2025029789","article-title":"Long term follow-up outcomes in congenital thrombotic thrombocytopenic purpura","volume":"146","author":"Stubbs","year":"2025","journal-title":"Blood"},{"issue":"25","key":"2026052811215547700_bib108","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026052811215547700_bib109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"Taylor","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026052811215547700_bib110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am J Hematol"},{"issue":"17","key":"2026052811215547700_bib111","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura","volume":"390","author":"Scully","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026052811215547700_bib112","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2026052811215547700_bib113","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2026052811215547700_bib114","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1111\/jth.13479","article-title":"Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam study","volume":"14","author":"Sonneveld","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"25","key":"2026052811215547700_bib115","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2026052811215547700_bib116","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2582\/2522800\/blood_bld-2025-030791-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2582\/2522800\/blood_bld-2025-030791-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:22:18Z","timestamp":1779981738000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/22\/2582\/566890\/Thrombotic-thrombocytopenic-purpura-celebrating-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":116,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030791","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,28]]},"published":{"date-parts":[[2026,5,28]]}}}